Cardiology

Study compares anticoagulants for antiphospholipid syndrome

(HealthDay)—In thrombotic antiphospholipid antibody syndrome (APS), rivaroxaban is not noninferior to dose-adjusted vitamin K antagonists (VKAs), according to a study published online Oct. 15 in the Annals of Internal Medicine.

Cardiology

Combo antithrombotic therapy increases bleeding risk

(HealthDay)—Patients with chronic coronary artery disease or peripheral artery disease treated with the combination of rivaroxaban and aspirin face a greater risk for bleeding versus patients treated with aspirin alone, ...

Medications

History of liver disease does not impact efficacy of edoxaban

(HealthDay)—For patients with atrial fibrillation (AF), the efficacy and safety of edoxaban versus warfarin is not altered with a history of liver disease, according to a study published in the July 16 issue of the Journal ...

page 9 from 40